Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
492
datasets available to search
ShareScore release 0.9.0
Dataset results
492 results for “EGFR mutations;”
A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
ClinicalTrials.gov study NCT01310036. IPD Sharing: Not stated. Countries: 4. Publications: 1.
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
ClinicalTrials.gov study NCT02759835. IPD Sharing: YES. Countries: 1. Publications: 2.
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
ClinicalTrials.gov study NCT00503971. IPD Sharing: NO. Countries: 1. Publications: 1.
Hypertrophic cardiomyopathy-associated mutations drive stromal activation via EGFR-mediated paracrine signaling
Open the record for dataset details and reuse information.
Data for: Identification of activating mutations in the transmembrane and extracellular domains of EGFR
<p>The epidermal growth factor receptor (EGFR) is frequently mutated in human cancer, most notably non-small-cell lung cancer and glioblastoma. While many frequently occurring EGFR mutations are known to confer constitutive EGFR activation, the situation is less clear for rarely detected variants. In fact, more than 1000 distinct EGFR mutations are listed in the Catalogue of Somatic Mutations in Cancer (COSMIC), but for most of them, the functional consequence is unknown. To identify additional, previously unknown activating mutations in EGFR, we screened a randomly mutated EGFR library for constitutive EGFR phosphorylation using a recently developed high-throughput approach termed PhosphoFlowSeq. Enrichment of the well-known activating mutations S768I, T790M, and L858R validated the experimental approach. Importantly, we also identified the activating mutations S442I and L658Q located in the extracellular and transmembrane domains of EGFR, respectively. To the best of our knowledge, neither S442I nor L658Q has been associated with an activating phenotype before. However, both have been detected in cancer samples. Interestingly, molecular dynamics (MD) simulations suggest that the L658Q mutation located in the hydrophobic transmembrane region forms intermolecular hydrogen bonds, thereby promoting EGFR dimerization and activation. Based on these findings, we screened the COSMIC database for additional hydrophilic mutations in the EGFR transmembrane region and indeed detected moderate constitutive activation of EGFR-G652R. Together, this study demonstrates that unbiased screening for activating mutations in EGFR not only yields well-established substitutions located in the kinase domain but also activating mutations in other regions of EGFR, including the extracellular and transmembrane domains.</p> <p> </p> <p>A. Wagner, E. Galicia-Andrés, M. Teufl, L. Gold, C. Obinger, P. Sykacek, C. Oostenbrink and M.W. Traxlmayr<br>Identification of activating mutations in the transmembrane and extracellular domains of EGFR<br>Biochemistry <strong>61</strong> (2022) 2049 – 2062<br>doi: <a href="https://doi.org/10.1021/acs.biochem.2c00384" target="_blank" rel="noopener">10.1021/acs.biochem.2c00384</a></p>
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastati
ClinicalTrials.gov study NCT06417814. IPD Sharing: YES. Countries: 27. Publications: 1.
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
ClinicalTrials.gov study NCT06194448. IPD Sharing: YES. Countries: 9. Publications: 1.
Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung Cancer
ClinicalTrials.gov study NCT01255150. IPD Sharing: Not stated. Countries: 5. Publications: 3.
Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases
ClinicalTrials.gov study NCT04808752. IPD Sharing: NO. Countries: 1. Publications: 1.
D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC
ClinicalTrials.gov study NCT04206072. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
ClinicalTrials.gov study NCT02500927. IPD Sharing: NO. Countries: 1. Publications: 1.
MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib
ClinicalTrials.gov study NCT03865511. IPD Sharing: NO. Countries: 1. Publications: 1.
Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC
ClinicalTrials.gov study NCT02353741. IPD Sharing: Not stated. Countries: 1. Publications: 1.
The HER Project: HRD in EGFR-mutated NSCLC
ClinicalTrials.gov study NCT07303218. IPD Sharing: Not stated. Countries: 1. Publications: 22.
A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Neoadjuvant Osimertinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harbouring EGFR Mutations
ClinicalTrials.gov study NCT04816838. IPD Sharing: NO. Countries: 1. Publications: 0.
Blood Detection of EGFR Mutation For Iressa Treatment
ClinicalTrials.gov study NCT02282267. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
ClinicalTrials.gov study NCT03653546. IPD Sharing: NO. Countries: 4. Publications: 1.
Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC
ClinicalTrials.gov study NCT03133234. IPD Sharing: NO. Countries: 1. Publications: 1.
Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.
ClinicalTrials.gov study NCT05754736. IPD Sharing: NO. Countries: 1. Publications: 3.
Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer
ClinicalTrials.gov study NCT02633189. IPD Sharing: Not stated. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.